Reducing the number of systematic biopsy cores in the era of MRI targeted biopsy—implications on clinically-significant prostate cancer detection and relevance to focal therapy planning
Background The optimal number of systematic biopsy cores in the era of multi-parametric MRI targeted biopsy remains unclear, especially on its impact of focal therapy planning. Our objective is to investigate the impact of reducing the number of systematic cores on prostate cancer detection in the e...
Gespeichert in:
| Veröffentlicht in: | Prostate cancer and prostatic diseases 2022-04, Vol.25 (4), p.720-726 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 726 |
|---|---|
| container_issue | 4 |
| container_start_page | 720 |
| container_title | Prostate cancer and prostatic diseases |
| container_volume | 25 |
| creator | Lee, Alvin Y. M. Chen, Kenneth Tan, Yu Guang Lee, Han Jie Shutchaidat, Vipatsorn Fook-Chong, Stephanie Cheng, Christopher W. S. Ho, Henry S. S. Yuen, John S. P. Ngo, Nye Thane Law, Yan Mee Tay, Kae Jack |
| description | Background
The optimal number of systematic biopsy cores in the era of multi-parametric MRI targeted biopsy remains unclear, especially on its impact of focal therapy planning. Our objective is to investigate the impact of reducing the number of systematic cores on prostate cancer detection in the era of MRI-US fusion targeted biopsy and as well as its relevance in template planning for focal therapy.
Materials and methods
A retrospective analysis of 398 consecutive men who underwent both systematic saturation (~24 cores) and MRI-US fusion targeted biopsy was performed. Four reduced-core systematic biopsy strategies (two-thirds, half, one-third and one-quarter systematic cores) were modelled and the detection rates of clinically-significant prostate cancer (csPCa defined as grade group ≥2) were compared to that of a full systematic biopsy using McNemar’s test. Focal therapy treatment plans were made based on positive cores on combined (targeted and systematic) biopsy and the various reduced-cores strategies to compare the proportion who had a change in treatment plan.
Results
csPCa was detected in 42% (168/398) of this patient cohort. Non-targeted systematic saturation biopsy had a 21% (83/398) csPCa detection rate. Our four strategies reduced the mean number of non-targeted systematic cores from 21.8 to 14.5, 10.9, 7.3 and 5.4 cores and their csPCa detection rates were significantly decreased to 16%, 13%, 9% and 8% respectively (all
p
|
| doi_str_mv | 10.1038/s41391-021-00485-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9705237</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2620078765</sourcerecordid><originalsourceid>FETCH-LOGICAL-c502t-dd33ca76b5009d8c250fa23a5e241fad03fd391d507d42dfd5a47d6ce2f040313</originalsourceid><addsrcrecordid>eNqFks1u1TAQhSMEoqXwAiyQJTZsAhM7jpMNEqr4qVSEVMHa8rWd1FViB9uplB0PwdvwNjwJk95L-VnAIkpG880ZH-cUxeMKnlfA2heprlhXlUDxgbrlJbtTHFe1aEreQHsXv1nDS9FyelQ8SOkKALqqg_vFEeNARdPBcfHtwppFOz-QfGmJX6adjST0JK0p20llp8nOhTmtRIdoE3H-BrRRbdT7izOSVRxstubAff_y1U3z6DTOBp9I8ESPzmM9jmuZ3OBdj4XPZI4hZZUtwUrjVoMqehsiyhsS7WivtwbJgfQBx7fFUc0rmUflPR75YXGvV2Oyjw7vk-LTm9cfT9-V5x_enp2-Oi812sylMYxpJZodR_-m1ZRDryhT3NK66pUB1hu8R8NBmJqa3nBVC9NoS3uogVXspHi5152X3WSNtj5HNco5uknFVQbl5J8d7y7lEK5lJ4BTJlDg2UEghs-LTVlOLmk7og8bliRpQwFEKxqO6NO_0KuwRI_2JP6xuu061v6HqkHwWnCGFN1TGm86RdvfHrkCuSVI7hMkMUHyJkFyG3ryu9nbkZ-RQYDtgYQtP9j4a_c_ZH8ACRfXLg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2740754753</pqid></control><display><type>article</type><title>Reducing the number of systematic biopsy cores in the era of MRI targeted biopsy—implications on clinically-significant prostate cancer detection and relevance to focal therapy planning</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Lee, Alvin Y. M. ; Chen, Kenneth ; Tan, Yu Guang ; Lee, Han Jie ; Shutchaidat, Vipatsorn ; Fook-Chong, Stephanie ; Cheng, Christopher W. S. ; Ho, Henry S. S. ; Yuen, John S. P. ; Ngo, Nye Thane ; Law, Yan Mee ; Tay, Kae Jack</creator><creatorcontrib>Lee, Alvin Y. M. ; Chen, Kenneth ; Tan, Yu Guang ; Lee, Han Jie ; Shutchaidat, Vipatsorn ; Fook-Chong, Stephanie ; Cheng, Christopher W. S. ; Ho, Henry S. S. ; Yuen, John S. P. ; Ngo, Nye Thane ; Law, Yan Mee ; Tay, Kae Jack</creatorcontrib><description>Background
The optimal number of systematic biopsy cores in the era of multi-parametric MRI targeted biopsy remains unclear, especially on its impact of focal therapy planning. Our objective is to investigate the impact of reducing the number of systematic cores on prostate cancer detection in the era of MRI-US fusion targeted biopsy and as well as its relevance in template planning for focal therapy.
Materials and methods
A retrospective analysis of 398 consecutive men who underwent both systematic saturation (~24 cores) and MRI-US fusion targeted biopsy was performed. Four reduced-core systematic biopsy strategies (two-thirds, half, one-third and one-quarter systematic cores) were modelled and the detection rates of clinically-significant prostate cancer (csPCa defined as grade group ≥2) were compared to that of a full systematic biopsy using McNemar’s test. Focal therapy treatment plans were made based on positive cores on combined (targeted and systematic) biopsy and the various reduced-cores strategies to compare the proportion who had a change in treatment plan.
Results
csPCa was detected in 42% (168/398) of this patient cohort. Non-targeted systematic saturation biopsy had a 21% (83/398) csPCa detection rate. Our four strategies reduced the mean number of non-targeted systematic cores from 21.8 to 14.5, 10.9, 7.3 and 5.4 cores and their csPCa detection rates were significantly decreased to 16%, 13%, 9% and 8% respectively (all
p
< 0.05). Compared to the reduced-core strategies, a full systematic saturation biopsy resulted in change to the focal therapy treatment plan in 12% (2/3 cores), 19% (1/2 cores), 24% (1/3 cores) and 29% (1/4 cores) of the time (
p
= 0.0434).
Conclusions
Reducing the number of systematic biopsies when performing an MRI-targeted biopsy leads to reduced detection of csPCa and alter the treatment plans for focal therapy, possibly limiting its oncological efficacy.</description><identifier>ISSN: 1365-7852</identifier><identifier>EISSN: 1476-5608</identifier><identifier>DOI: 10.1038/s41391-021-00485-3</identifier><identifier>PMID: 35027690</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>59/57 ; 631/67/589/466 ; 692/308/409 ; Biomedical and Life Sciences ; Biomedicine ; Biopsy ; Cancer Research ; Clinical significance ; Cores ; Humans ; Image-Guided Biopsy - methods ; Magnetic Resonance Imaging ; Male ; Planning ; Prostate - pathology ; Prostate cancer ; Prostatic Neoplasms - diagnostic imaging ; Prostatic Neoplasms - therapy ; Reproductive Medicine ; Retrospective Studies ; Saturation ; Therapy</subject><ispartof>Prostate cancer and prostatic diseases, 2022-04, Vol.25 (4), p.720-726</ispartof><rights>The Author(s) 2022. corrected publication 2022</rights><rights>2022. The Author(s).</rights><rights>The Author(s) 2022. corrected publication 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2022, corrected publication 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c502t-dd33ca76b5009d8c250fa23a5e241fad03fd391d507d42dfd5a47d6ce2f040313</citedby><cites>FETCH-LOGICAL-c502t-dd33ca76b5009d8c250fa23a5e241fad03fd391d507d42dfd5a47d6ce2f040313</cites><orcidid>0000-0003-3585-5431 ; 0000-0003-3252-8881</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/s41391-021-00485-3$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/s41391-021-00485-3$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35027690$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lee, Alvin Y. M.</creatorcontrib><creatorcontrib>Chen, Kenneth</creatorcontrib><creatorcontrib>Tan, Yu Guang</creatorcontrib><creatorcontrib>Lee, Han Jie</creatorcontrib><creatorcontrib>Shutchaidat, Vipatsorn</creatorcontrib><creatorcontrib>Fook-Chong, Stephanie</creatorcontrib><creatorcontrib>Cheng, Christopher W. S.</creatorcontrib><creatorcontrib>Ho, Henry S. S.</creatorcontrib><creatorcontrib>Yuen, John S. P.</creatorcontrib><creatorcontrib>Ngo, Nye Thane</creatorcontrib><creatorcontrib>Law, Yan Mee</creatorcontrib><creatorcontrib>Tay, Kae Jack</creatorcontrib><title>Reducing the number of systematic biopsy cores in the era of MRI targeted biopsy—implications on clinically-significant prostate cancer detection and relevance to focal therapy planning</title><title>Prostate cancer and prostatic diseases</title><addtitle>Prostate Cancer Prostatic Dis</addtitle><addtitle>Prostate Cancer Prostatic Dis</addtitle><description>Background
The optimal number of systematic biopsy cores in the era of multi-parametric MRI targeted biopsy remains unclear, especially on its impact of focal therapy planning. Our objective is to investigate the impact of reducing the number of systematic cores on prostate cancer detection in the era of MRI-US fusion targeted biopsy and as well as its relevance in template planning for focal therapy.
Materials and methods
A retrospective analysis of 398 consecutive men who underwent both systematic saturation (~24 cores) and MRI-US fusion targeted biopsy was performed. Four reduced-core systematic biopsy strategies (two-thirds, half, one-third and one-quarter systematic cores) were modelled and the detection rates of clinically-significant prostate cancer (csPCa defined as grade group ≥2) were compared to that of a full systematic biopsy using McNemar’s test. Focal therapy treatment plans were made based on positive cores on combined (targeted and systematic) biopsy and the various reduced-cores strategies to compare the proportion who had a change in treatment plan.
Results
csPCa was detected in 42% (168/398) of this patient cohort. Non-targeted systematic saturation biopsy had a 21% (83/398) csPCa detection rate. Our four strategies reduced the mean number of non-targeted systematic cores from 21.8 to 14.5, 10.9, 7.3 and 5.4 cores and their csPCa detection rates were significantly decreased to 16%, 13%, 9% and 8% respectively (all
p
< 0.05). Compared to the reduced-core strategies, a full systematic saturation biopsy resulted in change to the focal therapy treatment plan in 12% (2/3 cores), 19% (1/2 cores), 24% (1/3 cores) and 29% (1/4 cores) of the time (
p
= 0.0434).
Conclusions
Reducing the number of systematic biopsies when performing an MRI-targeted biopsy leads to reduced detection of csPCa and alter the treatment plans for focal therapy, possibly limiting its oncological efficacy.</description><subject>59/57</subject><subject>631/67/589/466</subject><subject>692/308/409</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Biopsy</subject><subject>Cancer Research</subject><subject>Clinical significance</subject><subject>Cores</subject><subject>Humans</subject><subject>Image-Guided Biopsy - methods</subject><subject>Magnetic Resonance Imaging</subject><subject>Male</subject><subject>Planning</subject><subject>Prostate - pathology</subject><subject>Prostate cancer</subject><subject>Prostatic Neoplasms - diagnostic imaging</subject><subject>Prostatic Neoplasms - therapy</subject><subject>Reproductive Medicine</subject><subject>Retrospective Studies</subject><subject>Saturation</subject><subject>Therapy</subject><issn>1365-7852</issn><issn>1476-5608</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqFks1u1TAQhSMEoqXwAiyQJTZsAhM7jpMNEqr4qVSEVMHa8rWd1FViB9uplB0PwdvwNjwJk95L-VnAIkpG880ZH-cUxeMKnlfA2heprlhXlUDxgbrlJbtTHFe1aEreQHsXv1nDS9FyelQ8SOkKALqqg_vFEeNARdPBcfHtwppFOz-QfGmJX6adjST0JK0p20llp8nOhTmtRIdoE3H-BrRRbdT7izOSVRxstubAff_y1U3z6DTOBp9I8ESPzmM9jmuZ3OBdj4XPZI4hZZUtwUrjVoMqehsiyhsS7WivtwbJgfQBx7fFUc0rmUflPR75YXGvV2Oyjw7vk-LTm9cfT9-V5x_enp2-Oi812sylMYxpJZodR_-m1ZRDryhT3NK66pUB1hu8R8NBmJqa3nBVC9NoS3uogVXspHi5152X3WSNtj5HNco5uknFVQbl5J8d7y7lEK5lJ4BTJlDg2UEghs-LTVlOLmk7og8bliRpQwFEKxqO6NO_0KuwRI_2JP6xuu061v6HqkHwWnCGFN1TGm86RdvfHrkCuSVI7hMkMUHyJkFyG3ryu9nbkZ-RQYDtgYQtP9j4a_c_ZH8ACRfXLg</recordid><startdate>20220401</startdate><enddate>20220401</enddate><creator>Lee, Alvin Y. M.</creator><creator>Chen, Kenneth</creator><creator>Tan, Yu Guang</creator><creator>Lee, Han Jie</creator><creator>Shutchaidat, Vipatsorn</creator><creator>Fook-Chong, Stephanie</creator><creator>Cheng, Christopher W. S.</creator><creator>Ho, Henry S. S.</creator><creator>Yuen, John S. P.</creator><creator>Ngo, Nye Thane</creator><creator>Law, Yan Mee</creator><creator>Tay, Kae Jack</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>M7Z</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-3585-5431</orcidid><orcidid>https://orcid.org/0000-0003-3252-8881</orcidid></search><sort><creationdate>20220401</creationdate><title>Reducing the number of systematic biopsy cores in the era of MRI targeted biopsy—implications on clinically-significant prostate cancer detection and relevance to focal therapy planning</title><author>Lee, Alvin Y. M. ; Chen, Kenneth ; Tan, Yu Guang ; Lee, Han Jie ; Shutchaidat, Vipatsorn ; Fook-Chong, Stephanie ; Cheng, Christopher W. S. ; Ho, Henry S. S. ; Yuen, John S. P. ; Ngo, Nye Thane ; Law, Yan Mee ; Tay, Kae Jack</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c502t-dd33ca76b5009d8c250fa23a5e241fad03fd391d507d42dfd5a47d6ce2f040313</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>59/57</topic><topic>631/67/589/466</topic><topic>692/308/409</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Biopsy</topic><topic>Cancer Research</topic><topic>Clinical significance</topic><topic>Cores</topic><topic>Humans</topic><topic>Image-Guided Biopsy - methods</topic><topic>Magnetic Resonance Imaging</topic><topic>Male</topic><topic>Planning</topic><topic>Prostate - pathology</topic><topic>Prostate cancer</topic><topic>Prostatic Neoplasms - diagnostic imaging</topic><topic>Prostatic Neoplasms - therapy</topic><topic>Reproductive Medicine</topic><topic>Retrospective Studies</topic><topic>Saturation</topic><topic>Therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lee, Alvin Y. M.</creatorcontrib><creatorcontrib>Chen, Kenneth</creatorcontrib><creatorcontrib>Tan, Yu Guang</creatorcontrib><creatorcontrib>Lee, Han Jie</creatorcontrib><creatorcontrib>Shutchaidat, Vipatsorn</creatorcontrib><creatorcontrib>Fook-Chong, Stephanie</creatorcontrib><creatorcontrib>Cheng, Christopher W. S.</creatorcontrib><creatorcontrib>Ho, Henry S. S.</creatorcontrib><creatorcontrib>Yuen, John S. P.</creatorcontrib><creatorcontrib>Ngo, Nye Thane</creatorcontrib><creatorcontrib>Law, Yan Mee</creatorcontrib><creatorcontrib>Tay, Kae Jack</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Biochemistry Abstracts 1</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Prostate cancer and prostatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lee, Alvin Y. M.</au><au>Chen, Kenneth</au><au>Tan, Yu Guang</au><au>Lee, Han Jie</au><au>Shutchaidat, Vipatsorn</au><au>Fook-Chong, Stephanie</au><au>Cheng, Christopher W. S.</au><au>Ho, Henry S. S.</au><au>Yuen, John S. P.</au><au>Ngo, Nye Thane</au><au>Law, Yan Mee</au><au>Tay, Kae Jack</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Reducing the number of systematic biopsy cores in the era of MRI targeted biopsy—implications on clinically-significant prostate cancer detection and relevance to focal therapy planning</atitle><jtitle>Prostate cancer and prostatic diseases</jtitle><stitle>Prostate Cancer Prostatic Dis</stitle><addtitle>Prostate Cancer Prostatic Dis</addtitle><date>2022-04-01</date><risdate>2022</risdate><volume>25</volume><issue>4</issue><spage>720</spage><epage>726</epage><pages>720-726</pages><issn>1365-7852</issn><eissn>1476-5608</eissn><abstract>Background
The optimal number of systematic biopsy cores in the era of multi-parametric MRI targeted biopsy remains unclear, especially on its impact of focal therapy planning. Our objective is to investigate the impact of reducing the number of systematic cores on prostate cancer detection in the era of MRI-US fusion targeted biopsy and as well as its relevance in template planning for focal therapy.
Materials and methods
A retrospective analysis of 398 consecutive men who underwent both systematic saturation (~24 cores) and MRI-US fusion targeted biopsy was performed. Four reduced-core systematic biopsy strategies (two-thirds, half, one-third and one-quarter systematic cores) were modelled and the detection rates of clinically-significant prostate cancer (csPCa defined as grade group ≥2) were compared to that of a full systematic biopsy using McNemar’s test. Focal therapy treatment plans were made based on positive cores on combined (targeted and systematic) biopsy and the various reduced-cores strategies to compare the proportion who had a change in treatment plan.
Results
csPCa was detected in 42% (168/398) of this patient cohort. Non-targeted systematic saturation biopsy had a 21% (83/398) csPCa detection rate. Our four strategies reduced the mean number of non-targeted systematic cores from 21.8 to 14.5, 10.9, 7.3 and 5.4 cores and their csPCa detection rates were significantly decreased to 16%, 13%, 9% and 8% respectively (all
p
< 0.05). Compared to the reduced-core strategies, a full systematic saturation biopsy resulted in change to the focal therapy treatment plan in 12% (2/3 cores), 19% (1/2 cores), 24% (1/3 cores) and 29% (1/4 cores) of the time (
p
= 0.0434).
Conclusions
Reducing the number of systematic biopsies when performing an MRI-targeted biopsy leads to reduced detection of csPCa and alter the treatment plans for focal therapy, possibly limiting its oncological efficacy.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>35027690</pmid><doi>10.1038/s41391-021-00485-3</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0003-3585-5431</orcidid><orcidid>https://orcid.org/0000-0003-3252-8881</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1365-7852 |
| ispartof | Prostate cancer and prostatic diseases, 2022-04, Vol.25 (4), p.720-726 |
| issn | 1365-7852 1476-5608 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9705237 |
| source | MEDLINE; SpringerLink Journals |
| subjects | 59/57 631/67/589/466 692/308/409 Biomedical and Life Sciences Biomedicine Biopsy Cancer Research Clinical significance Cores Humans Image-Guided Biopsy - methods Magnetic Resonance Imaging Male Planning Prostate - pathology Prostate cancer Prostatic Neoplasms - diagnostic imaging Prostatic Neoplasms - therapy Reproductive Medicine Retrospective Studies Saturation Therapy |
| title | Reducing the number of systematic biopsy cores in the era of MRI targeted biopsy—implications on clinically-significant prostate cancer detection and relevance to focal therapy planning |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T01%3A00%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Reducing%20the%20number%20of%20systematic%20biopsy%20cores%20in%20the%20era%20of%20MRI%20targeted%20biopsy%E2%80%94implications%20on%20clinically-significant%20prostate%20cancer%20detection%20and%20relevance%20to%20focal%20therapy%20planning&rft.jtitle=Prostate%20cancer%20and%20prostatic%20diseases&rft.au=Lee,%20Alvin%20Y.%20M.&rft.date=2022-04-01&rft.volume=25&rft.issue=4&rft.spage=720&rft.epage=726&rft.pages=720-726&rft.issn=1365-7852&rft.eissn=1476-5608&rft_id=info:doi/10.1038/s41391-021-00485-3&rft_dat=%3Cproquest_pubme%3E2620078765%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2740754753&rft_id=info:pmid/35027690&rfr_iscdi=true |